Clinical Information

Clinical Information

Dosing

TURALIO offers straightforward, twice-daily oral dosing for TGCT1

The recommended dose of TURALIO is 400 mg taken twice daily for a total of 800 mg per day. TURALIO should be taken on an empty stomach: no food or snack at least 2 hours before taking it and at least 1 hour after taking it.

Have patients follow these instructions when taking TURALIO:

  • It’s important to swallow capsules whole and not open, break, or chew them
  • If patients vomit or miss a dose of TURALIO, they should take the next dose at its scheduled time

Recommended dosage and dosage adjustments1

Recommended TURALIO dose reductions for adverse reactions

Recommended starting dose 800 mg
total daily dose
400 mg twice daily
First dose reduction 600 mg
total daily dose
200 mg in the morning and
400 mg in the evening
Second dose reduction 400 mg
total daily dose
200 mg twice daily
Permanently discontinue TURALIO in patients who are unable to tolerate 200 mg orally twice daily.
  • The recommended dosage modifications for TURALIO for adverse reactions are summarized in Table 2 of the TURALIO full Prescribing Information
  • Avoid concomitant use of TURALIO with moderate or strong CYP3A inhibitors or UGT inhibitors during treatment with TURALIO. If concomitant use with a moderate or strong CYP3A inhibitor or UGT inhibitor cannot be avoided, reduce the TURALIO dose according to the recommendation in Table 3 of the TURALIO full Prescribing Information. If concomitant use of a moderate or strong CYP3A inhibitor or UGT inhibitor is discontinued, increase the TURALIO dose (after 3 plasma half-lives of the moderate or strong CYP3A inhibitor or UGT inhibitor) to the dose that was used before starting the inhibitor
  • The recommended dosage of TURALIO for patients with mild to severe renal impairment (creatinine clearance [CLcr] 15 to 89 mL/min estimated by Cockcroft-Gault using actual body weight) is 200 mg in the morning and 400 mg in the evening
Refer to TURALIO full Prescribing Information for additional dosing guidelines.
CYP3A, cytochrome P450, family 3, subfamily A; UGT, uridine diphosphate glucuronosyltransferase.

Prescribing TURALIO1 Because of the risk of hepatotoxicity, TURALIO is available only through a Risk Evaluation and Mitigation Strategy (REMS) program. Under TURALIO REMS, only certified healthcare providers and pharmacies may prescribe and dispense TURALIO. In addition, a registry is used to collect information about the effects of taking TURALIO over time. Patients must complete and sign an enrollment form for the TURALIO REMS Program and the registry.

Further information is available at turalioREMS.com or by telephone at 1-833-887-2546.
Further information is available at turalioREMS.com or by telephone at
1-833-887-2546.